Company news
PharmAla Biotech Holdings, Inc. news in 2026
PharmAla Biotech Holdings, Inc.'s news releases, calls and decks from 2026, newest first.
PharmAla Biotech Signs Supply and Data Agreement with Aalborg University Hospital for Danish Randomized Trial of MDMA-Assisted Treatment for Service-Related PTSD
November 9, 2026
PharmAla Signs Agreement and Initiates R&D with Corealis Pharma for GMP Manufacturing of its patented ALA-002 Drug Product
November 5, 2026
Rua Bioscience and PharmAla Biotech partner to supply medicinal MDMA in New Zealand
October 8, 2026
PharmAla Biotech Provides Corporate Update, Change of Auditor, Retention of Watertower Research and Oak Hill
September 18, 2026
PharmAla Biotech Provides Corporate Update: Change of Auditor, Retention of Watertower Research and Oak Hill
September 17, 2026
PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner
August 21, 2026
PharmAla Issues Q3 Financial Statements and AGM Update
July 30, 2026
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
July 21, 2026
PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset
July 6, 2026
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
May 20, 2026
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
May 13, 2026
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
April 27, 2026
PharmAla Issues Q2 Financial Statements and Grants Options
April 21, 2026
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order
April 20, 2026
PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders
March 3, 2026
PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia
February 26, 2026
PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data
February 23, 2026
PharmAla Announces Changes to Board of Directors
February 10, 2026
PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research
January 8, 2026